IMV Chief Executive Bows Out

Dartmouth drug discovery company IMV is replacing its CEO.
Former Chief Executive Frederic Ors stepped down Wednesday, with Chief Business Officer Andrew Hall slated to serve as interim CEO until the Board of Directors hires a permanent replacement for Ors.
IMV is developing “a new class of targeted cancer immunotherapies” and has developed compounds that allow for the delayed release of